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The Effects of Cannabidiol on Aqueous Humor Outflow and
Trabecular Meshwork Cell Signaling
Alyssa S. Aebersold and Zhao-Hui Song *
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* Correspondence: zhsong@louisville.edu; Tel.: +1-502-852-5160

Abstract: Intraocular pressure (IOP) is regulated primarily through aqueous humor production by
ciliary body and drainage through uveoscleral and trabecular meshwork (TM) tissues. The goal of this
study was to measure the effect of non-psychotropic cannabidiol (CBD) on aqueous humor outflow
through TM and assess the effect of CBD on the TM cell signaling pathways that are important for
regulating outflow. Perfused porcine eye anterior segment explants were used to investigate the
effects of CBD on aqueous humor outflow. Cultured porcine TM cells were used to study the effects
of CBD on TM cell contractility, myosin light chain (MLC) and myosin phosphatase targeting subunit
1 (MYPT1) phosphorylation, and RhoA activation. In the anterior segment perfusion experiments,
aqueous humor outflow was increased significantly within 1 h after adding 1 µM CBD and the effect
was sustained over the 5 h of measurement. Treatment of TM cells with 1 µM CBD significantly
decreased TM cell-mediated collagen contraction, inhibited phosphorylation of MLC and MYPT1,
and reduced RhoA activation. Our data demonstrate, for the first time, that as a potential therapeutic
agent for lowering intraocular pressure, CBD can enhance aqueous humor outflow and modify TM
cell signaling.
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1. Introduction
Glaucoma is one of the leading causes of human blindness, with chronically elevated intraocular pressure (IOP) as the major risk factor [1–3]. IOP is regulated through
a dynamic balance of aqueous humor secretion by the ciliary body and outflow via the
trabecular meshwork (TM) and uveoscleral routes [1–3]. Therefore, IOP can be lowered
by decreasing aqueous humor formation or increasing aqueous outflow (through either
TM or uveoscleral routes). Current pharmacotherapies for glaucoma include prostaglandin
analogs, β-adrenoceptor antagonists, α-adrenoceptor agonists, carbonic anhydrase inhibitors, cholinergic agonists, and most recently, Rho kinase inhibitors [4–8]. However,
existing drugs have side-effects and patients frequently become tolerant to the drugs over
the course of their disease (available drugs no longer lower IOP). Therefore, there is an
urgent need for novel drugs to lower IOP through novel mechanisms of action with fewer
side effects [4–8].
Cannabidiol (CBD) is one of the major active constituents of cannabis [9,10]. Unlike ∆9 -tetrahydrocannabinol (∆9 -THC), CBD is non-psychotropic [9,10]. CBD has a wide
range of therapeutic potentials, including the treatment of cancer [11], inflammatory diseases [12], neurodegenerative diseases [13,14], and psychiatric diseases [15]. Recently, CBD
(Epidiolex/Epidyolex)) received both food and drug administration (FDA) and European
Medicines Agency (EMA) approvals for treating epilepsy in children; this is the first time a
constituent isolated from cannabis has been FDA approved [16].
The observation that smoked marijuana lowers IOP was first noted more than 50 years
ago [17]. Since then, many papers have demonstrated that various phytocannabinoids,
including ∆9 -THC and CBD, are able to lower IOP, suggesting their potentials as therapeutic
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agents for glaucoma [18–20]. However, ∆9 -THC has psychotropic side-effects which limit
its clinical use for glaucoma [18,20]. Since CBD is non-psychotropic, its IOP-lowering effects
have more therapeutic potential.
The Rho/Rho kinase signaling pathway is a major regulator of conventional aqueous
humor outflow through the TM [21–25]. This pathway regulates phosphorylation of
downstream regulators regulatory myosin light chain (MLC) and myosin phosphatase
target subunit 1 (MYPT1) [26]. By preventing the phosphorylation of MLC and MYPT1,
Rho kinase inhibitors such as Rhopressa (Netarsudil) and Galantec (Ripasudil), inhibit TM
tissue contraction and enhance aqueous humor outflow through the TM [21–25,27–29].
Despite evidence that CBD reduces IOP, the underlying molecular mechanism has not
been elucidated. One potential mechanism is that CBD enhances aqueous outflow in the
TM, but this has not been studied. In this study we first investigated if CBD modulates
aqueous humor outflow using perfused porcine anterior segments. We then investigated
whether CBD alters the contractility of cultured porcine TM cells and the involvement of
the Rho/Rho kinase signaling pathways in the effects of CBD on TM cells. We chose 1 µM
concentration of CBD for this study because it has been shown that at this concentration
CBD acts specifically on its multiple molecular targets to produce its pharmacological
effects [30].
2. Materials and Methods
2.1. Porcine Anterior Segment–Perfused Organ Culture Model
It has been shown that in the anterior segment perfused organ culture model, flow
rates are physiological (approximately 2.75 µL/min) and outflow is through the TM [31–35].
Porcine anterior segment perfused organ culture was performed as previously described [31–35].
Within 30 min of decapitation, fresh porcine eyes were collected from a local slaughterhouse.
Ciliary body and iris were carefully removed, and anterior segment explants were prepared
to contain the undisturbed TM, a 2 to 5 mm rim of sclera and intact cornea. Subsequently,
the porcine anterior segments were mounted in a custom-made perfusion culture apparatus
and perfused with Dulbecco’s modified Eagles medium (DMEM). Organ cultures were
maintained with 5% CO2 at 37 ◦ C. A constant perfusion head of 10 cm (~7.35 mm Hg)
was used for perfusion and outflow was stabilized for at least 5 h. For CBD or vehicle
experiments, the explants that stabilized between 1.5 and 8 µL/min at 7.35 mmHg were
used. After stabilization, CBD (Cayman Chemical, Ann Arbor, MI, USA) was introduced.
The anterior segments were then perfused continuously with CBD-containing medium
for 5 h, and the outflow was monitored. Medium containing no CBD was run in parallel.
Aqueous humor outflow was calculated as the rate of flow of perfusate (in microliters per
minute). Drug effects were evaluated in each explant as the percentage change of outflow
in drug-treated eyes over pre-drug baseline outflow. Ten eyes were used for each group
of treatment.
2.2. Porcine Trabecular Meshwork Cell Cultures
Previously published methods were adapted to culture primary porcine TM cells [36,37].
Briefly, blunt dissections were used to isolate TM from fresh porcine eyes. TM cells were
cultured in DMEM with 5% CO2 at 37 ◦ C. In addition to their morphology, the identity of
TM cells was established by their ability to secrete tissue plasminogen activator and to take
up acetylated low-density lipoprotein and [36,37].
2.3. Collagen Gel Contraction Assays
Collagen gel contractility assays were performed following previously published procedures [38]. The wells of 24-well cell culture plates (Corning, Corning, NY, USA) were each
coated with 1 mL 1% bovine serum albumin (BSA) for 1 h at 37 ◦ C. Porcine TM cells were
collected by treatment of cultures with trypsin-ethylenediaminetetraacetic acid (EDTA),
washed with 1× PBS, and re-suspended in DMEM at a density of 1 × 106 cells/mL. Rat tail
collagen type I (Santa Cruz Bio, Dallas, TX, USA), 10X phosphate buffered saline (PBS), ster-
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ile dH2 O, and 1 N NaOH were mixed at ratios following manufacturer instructions to obtain
a final concentration of 1.9 mg/mL collagen and final cell density of 2 × 105 cells/mL. The
resultant mixture was added to BSA coated wells (1% BSA, 0.5 mL/well). Collagen gels
were allowed to polymerize at 37 ◦ C with 5% CO2 for 90 min. Once released from the
wells, serum-free DMEM (0.5 mL), with or without CBD, was added to the gels. The gels
were imaged at 48 h. The area of the collagen gels was calculated using ImageJ software
(National Institutes of Health, Bethesda, MD, USA). For normalization, the area of the
collagen gel containing vehicle treated TM cells was set at 100%, and the changes in the
area for CBD treatment are shown as a bar graph representing the mean ± SEM (n = 5).
2.4. Western Blot Analysis
Porcine TM cell proteins were prepared as previously described [39]. After incubating
at 100 ◦ C with 2× Laemmli buffer under reducing conditions for 20 min, protein bands
were resolved on a 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel. Subsequently,
protein bands were transferred onto a nitrocellulose membrane and the membranes was
incubated for 1 h in 5% nonfat milk in Tris-buffered saline with Tween® 20 (TBS-T) (10 mM
Tris-HCl, 150 mM NaCl, and 0.3% Tween 20, pH 8.0). The membrane was thenincubated
overnight at 4 ◦ C with primary anti-glyceraldehyde-3-phosphate dehydrogenase (antiGAPDH) and anti-phospho-MLC2 (Ser19) or anti-phospho-MYPT1 (Thr853) antibody (Cell
Signaling, Beverly, MA, USA). Subsequently, the membranes were washed three times with
TBS-T buffer for 5 min, and then incubated with horseradish peroxidase (HRP)–conjugated
secondary antibody (Santa Cruz Biotechnology, Dallas, TX, USA) at room temperature for
1 h. The membrane was then washed with TBS-T buffer for three times (each time 5 min)
and the antibody-bound protein bands were developed using enhanced chemiluminescence
Western blotting substrate from Pierce™ (Fisher Scientific, Waltham, MA, USA).
2.5. RhoA Activation Assay
Samples were collected and assays were performed according to manufacturer’s (Cytoskeleton Inc., Denver, CO, USA) instructions. Cells were grown to confluence and serum
starved overnight. Cells were then treated with vehicle or CBD, lysed on ice using lysis
buffer (50 mM Tris, 10 mM MgCl2 , 0.5 M NaCl, 0.1% Triton X-100, and 0.1% SDS, pH 7.5)
containing a protease inhibitor cocktail (Sigma, St. Louis, MO, USA), then collected into
pre-chilled 1.5 mL microcentrifuge tubes. Cell lysates were then centrifuged at 10,000× g at
4 ◦ C, and supernatant containing 50 µg of protein was incubated with 10 µg Rhotekin-RBD
beads (Cytoskeleton, Denver, CO, USA) in a final volume of 300 µL for 1 h at 4 ◦ C. Following
incubation, beads were washed with ice-cold wash buffer and centrifuged at 5000× g. The
immunoprecipitated complex was re-suspended in 2× SDS sample buffer, boiled at 100 ◦ C
for 5 min, and then subjected to 10% SDS- polyacrylamide gel electrophoresis, followed by
Western blot analysis. The separated proteins were immunoblotted with antibody against
RhoA (Cytoskeleton Inc., Denver, CO, USA).
2.6. Data Analysis
For anterior segment perfusion studies, results are presented as changes in aqueous
humor outflow (% of basal) mean ± SEM. The level of significance was chosen as p < 0.05.
For the collagen gel contraction assay, images of gel areas were quantified with the use
of ImageJ program (NIH, Bethesda, MD, USA). For Western blot assays, the bands on
X-ray films were scanned by the Epson Perfection V39 (Epson, Long Beach, CA, USA)
and were quantified with the use of ImageJ. All data are analyzed and plotted with Prism
software (GraphPad, San Diego, CA, USA). Unpaired two-tailed Student’s t-tests were used
to compare the mean ± SEM of CBD and vehicle treatment groups. The level of significance
for all studies was set at p < 0.05.

(GraphPad, San Diego, CA, USA). Unpaired two-tailed Student’s t-tests were used t
pare the mean ± SEM of CBD and vehicle treatment groups. The level of significan
all studies was set at p < 0.05.
Cells 2022, 11, 3006

3. Results

4 of 10

3.1. The Effects of CBD on Aqueous Humor Outflow

3. Results
Aqueous humor outflow studies were performed using the porcine anterior se
3.1.
The
of CBD
on Aqueous
Humor
Outflow in Figure 1, the application of 1 µM CBD
perfusedEffects
organ
culture
model.
As shown

Aqueous humor
outflow
studies
were performed
using
the porcine
anterior
segment with v
than doubled
aqueous
humor
outflow
at 1 h after
treatment
when
compared
perfused
organ
culture
model.
As
shown
in
Figure
1,
the
application
of
1
µM
CBD
more
This effect lasted for the measurement window of 5 h.
than doubled aqueous humor outflow at 1 h after treatment when compared with vehicle.
This effect lasted for the measurement window of 5 h.

Figure 1. Effects of cannabidiol on aqueous humor outflow. Application of 1 µM CBD caused a

Figure
1. Effects
cannabidiol
aqueous
humor
Application
of 1 µM
significant
increaseof
in aqueous
humoron
outflow
lasting
from 1 outflow.
h to 5 h. Basal
outflow is defined
as CBD ca
the averageincrease
outflow ofin
theaqueous
three timehumor
points prior
to CBD
administration.
expressed
as is def
significant
outflow
lasting
from 1 hResults
to 5 h.are
Basal
outflow
mean
± SEM;outflow
n = 10. *of
Significant
between
1 µM
CBD and
vehicle (DMEM
+ 0.001%
the
average
the threedifferences
time points
prior
to CBD
administration.
Results
are expre
ethanol)
determined
by
t-test,
p
<
0.05.
mean ± SEM; n = 10. * Significant differences between 1 µM CBD and vehicle (DMEM +
ethanol)
t-test, p Gel
< 0.05.
3.2. The determined
Effect of CBD by
on Collagen
Contraction Mediated by TM Cells
To determine if collagen contraction mediated by TM cells is altered by CBD, TM

3.2.
The
Effect
of CBD
Collagen Gel Contraction
byinTM
Cells
cells
were
cultured
in aon
three-dimensional
collagen gel,Mediated
and change
area
of the gel in

response
to DMEM (vehicle)
or DMEM
containingmediated
CBD (1 µM)
wasismeasured.
To determine
if collagen
contraction
bytreatment
TM cells
altered by CB
As shown in Figure 2, vehicle treated TM cells caused collagen contraction. Importantly,
cells
were
cultured
in
a
three-dimensional
collagen
gel,
and
change
in area of the
CBD treatment significantly opposed TM cell-mediated gel contraction (CBD gel area
response
DMEM
(vehicle)
or DMEM
CBD (1
µM) treatment
was mea
118.7% ± to
3.042
compared
to vehicle,
n = 5; p <containing
0.05). These results
demonstrate
that CBD
As
shown
2, vehicle treated TM cells caused collagen contraction. Impor
relaxes
TM in
cellFigure
contraction.

CBD treatment significantly opposed TM cell-mediated gel contraction (CBD ge
3.3. The Effects of CBD on MLC Phosphorylation in TM Cells
118.7% ± 3.042 compared to vehicle, n = 5; p < 0.05). These results demonstrate tha
To determine the constitutive level of MLC phosphorylation and whether CBD stimurelaxes
TM cell
lation would
altercontraction.
phosphorylation of MLC in TM cells, cells were serum starved overnight
followed by treatment with vehicle, or CBD (1 µM) for 2 h. As shown in Figure 3, MLC is
constitutively phosphorylated in TM cells. Following treatment with CBD, MLC phosphorylation significantly decreased by 51.56% (mean ± SEM: 48.44 ± 6.268; p < 0.05). These
results demonstrate that in TM cells CBD inhibits MLC phosphorylation.
3.4. The Effects of CBD on MYPT1 Phosphorylation in TM Cells
To determine if MYPT1 phosphorylation is altered by CBD, TM cells were serum
starved overnight followed by treatment with DMEM medium or DMEM containing CBD
(1 µM) for 2 h. As shown in Figure 4, following treatment with CBD, MYPT1 phosphorylation at Thr853 significantly decreased by 53.66% (mean ± SEM: 46.34 ± 11.95; p < 0.05).
These results demonstrate that in TM cells CBD inhibits MYPT1 phosphorylation

Cells 2022, 11, x FOR PEER REVIEW
Cells 2022, 11, 3006

5 of 10

Figure 2. Effect of cannabidiol on collagen gel contraction mediated by trabecular meshwork
Cells grown embedded in collagen gels were treated with DMEM or DMEM containing 1 µM
for 48 h. Top: Representative photographs of collagen gel cultures of TM cells incubated fo
with the indicated drug treatment. Bottom: The mean ± SEM of results of five experimen
shown. Treatment with CBD significantly opposed the basal level of gel contraction. * Sign
difference from vehicle determined by t-test, p < 0.05.
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Figure 4. Effect of cannabidiol on myosin phosphatase targeting subunit 1 (MYPT1) phosphorylation. (A): Western blot representative of phosphorylation of myosin phosphatase targeting subunit
1 (MYPT1) at Thr853 for three experiments is shown. TM cells were serum starved overnight and
treated with vehicle or 1 µM CBD for 2 h, then phosphorylation of MYPT1 at Thr853 was assessed.
(B): densitometry quantification of phospho-MYPT1 from three experiments is shown. Following
treatment with CBD, MYPT1 phosphorylation at Thr853 significantly decreased. Results are expressed
as mean ± SEM (n = 3). Vehicle treated phosphorylation of MYPT1 levels are normalized to 100%.
* Significant difference from vehicle determined by t-test, p < 0.05.
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Figure 5. The effect of cannabidiol on RhoA activation. (A): representative Western blot of RhoAGTP and Total RhoA for three experiments is shown. TM cells were serum starved overnight and
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phosphorylating MYPT1, thereby inactivating MLCP and inhibiting its phosphatase activity,
and allowing sustained contraction [26,44]. In the current study, our results showed a decrease in MYPT1 Thr853 phosphorylation in response to CBD, indicating MLCP activation
and MLC dephosphorylation.
Furthermore, our data demonstrated that RhoA activation was inhibited by CBD. This
finding further supports the notion that CBD inhibits Rho/Rho kinase pathway, enhances
dephosphorylation of MLC, and to the same end decreases the contractility of TM cells and
allows for enhanced aqueous humor outflow.
In addition to having been approved for treating epilepsy in children, CBD is currently
in clinical trials for a variety of diseases, including general pain and pain associated disorders, drug abuse and use disorders, other neurologic conditions and psychiatric conditions,
and COVID-19 (from clinicaltrials.gov, accessed on 15 August 2022). Furthermore, there is
an increasing interest by the public in the dietary supplement and potential therapeutic
uses of CBD [45]. However, CBD use is not risk-free. Human studies have reported adverse
effects of CBD including gastrointestinal issues, drowsiness, fatigue, and the most serious
adverse side effect of CBD is elevated liver enzymes in liver function test [46,47].
Regarding the potential adverse effects for the eye, a recently published study in mice
showed an increase in intraocular pressure (IOP) following topical application of a high
concentration of CBD [48]. On the contrary, in another study also conducted in mice, CBD
was shown to have no effects or decrease IOP, depending on the doses applied topically [49].
It is likely that the effects of CBD on IOP are dose related. Therefore, in the future it is
important to examine the concentration-response of the CBD on aqueous humor outflow.
In addition, in the future it is important to compare the efficacy of CBD with other drugs
known to enhance aqueous humor outflow. Currently, the most frequently used route of
administration of CBD for patients is oral intake of CBD oil. In the future it is crucial to
study dose–response of CBD on IOP in patients to see if oral intake of CBD oil is beneficial
or detrimental on IOP.
5. Conclusions
In summary, in this study we discovered, for the first time, that at 1 µM concentration
CBD increases aqueous humor outflow in perfused anterior segments. In addition, using
cultured TM cells, we demonstrated that CBD at 1 µM concentration inhibits TM cell
contractility, MLC phosphorylation, MYPT1 phosphorylation and RhoA activation. Overall,
our data support the concept that by altering the Rho/Rho kinase signaling to MLC, CBD
was able to decrease the contractility of TM cells and enhance aqueous humor outflow via
the TM route. There are many IOP-lowering drugs available to reduce aqueous humor
production, but there are only limited drugs available to increase aqueous humor outflow
directly through the TM route. This study demonstrated that as a potential therapeutic
agent for lowering IOP, CBD is able to modify TM cell signaling and enhance aqueous
humor outflow, which is often blocked in glaucoma.
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